Patient-reported outcomes (PROs) can enhance drug development, but the integration of PRO measures as end points in phase 3 clinical trials has been slow. The FDA held a two-day workshop to gather input on a series of drug development documents they are developing to provide guidance to stakeholders on collecting information on patient experiences to inform product development. (